Memantine Merz (Memantine Hydrochloride)

Memantine is used in the management of Alzheimer’s disease, targeting glutamatergic neurotransmission to improve cognitive function.

• Moderate to severe Alzheimer’s disease: helps slow cognitive decline and functional deterioration.
• Combination therapy with cholinesterase inhibitors: provides additional cognitive benefit when used together.
• Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression associated with disease progression.

• Memantine acts as a non‑competitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by overstimulation with glutamate, thereby reducing excitotoxic neuronal injury that contributes to the progression of Alzheimer’s disease.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate cranial pain.
• Constipation: reduced bowel movements.
• Confusion: transient disorientation or difficulty concentrating.
• Somnolence: increased sleepiness or fatigue.

Serious or Rare Side Effects

• Seizures: occurrence of convulsive episodes.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Stevens‑Johnson syndrome: serious skin and mucous membrane disorder.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Cardiac arrhythmias: irregular heart rhythm potentially requiring medical attention.

Memantine should be used with caution in specific clinical situations.

• Renal impairment: assess kidney function and consider dose adjustment.
• History of seizures: monitor for increased seizure activity.
• Concurrent NMDA antagonists: avoid additive neuro‑psychiatric effects.
• Pregnancy: prescribe only if the potential benefit justifies the potential risk to the fetus.
• Elderly patients: initiate therapy at the lowest effective dose and titrate slowly.
• Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Memantine may interact with other medications that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid)

• Amantadine: combined NMDA antagonism can increase neuro‑psychiatric adverse effects.
• Ketamine: additive CNS depression and dissociative symptoms.
• Other NMDA receptor antagonists: heightened risk of severe side effects.

Moderate Interactions (Monitor Closely)

• Antihypertensives: possible enhancement of hypotensive effect.
• CNS depressants (e.g., benzodiazepines): increased sedation or drowsiness.
• Acetylcholinesterase inhibitors: may reduce therapeutic efficacy of memantine.